Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) are shown between white blood cells in urinary microscopy. Credit: Steven Fruitsmaak / commons.wikimedia.org.

Recce Pharmaceuticals has selected CMAX Clinical Research in South Australia as the independent trial facility for a Phase I/II intravenous (IV) trial of RECCE 327 (R327) to treat urinary tract infections (UTI).

The Phase I/II trial has been designed for assessing and evaluating R327 as an IV dose at fast infusion rates of 15 to 30 minutes across three cohorts of nearly 12 participants, with first participants anticipated to be dosed in the first quarter of this year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the trial, plasma and urine from the participants will be collected at various time points during and after dosing.

These samples will be used for assessing the concentrations and antibacterial effect of R327 in the urine on various bacterial strains.

Recce stated that the data from the trial will support R327’s advancement as a broad spectrum anti-infective across all types of UTIs, including simple, complicated, and recurring.

See Also:

A Phase II trial in UTI patients is anticipated to be commenced in the second half of the year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In a Phase I study, R327 was found to be given safely.

Recce Pharmaceuticals CEO James Graham said: “We are thrilled to be building upon the successes of a recent Phase I study with the team at CMAX.

“The opportunity of showcasing R327’s potential to change the treatment paradigm for patients suffering from serious infections strengthens its position as a fast-acting, broad-spectrum anti-infective.”

IV and topical therapy R327 is being developed to treatment serious and potentially life-threatening infections that are caused due to Gram-positive and Gram-negative bacteria, including their superbug forms.